Revisiting RAAS blockade in CKD with newer potassium-binding drugs

Kidney International

Volumn 93, Issue 2, 2018, Pages 325-334

  Georgianos, Panagiotis I ^a   Agarwal, Rajiv ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; hyperkalemia; patiromer; RAAS blockade; sodium zirconium cyclosilicate

Indexed keywords

PATIROMER; SODIUM ZIRCONIUM CYCLOSILICATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CHELATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SHORT SURVEY; ANIMAL; BLOOD; DRUG EFFECT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOMARKERS; CHELATING AGENTS; HUMANS; HYPERKALEMIA; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TREATMENT OUTCOME;

EID: 85038858546     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.08.038     Document Type: Short Survey

References (57)

1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:5 suppl 2 (2004), 1–290.
2. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31 (2013), 1281–1357.
3. Sarafidis, P.A., Ruilope, L.M., Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. Kidney Int 85 (2014), 536–546.
4. Wheeler, D.C., Becker, G.J., Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int 83 (2013), 377–383.
5. Sarafidis, P.A., Khosla, N., Bakris, G.L., Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49 (2007), 12–26.
6. Lazich, I., Bakris, G.L., Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 34 (2014), 333–339.
7. Weir, M.R., Rolfe, M., Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5 (2010), 531–548.
8. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
9. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med 367 (2012), 2204–2213.
10. Palmer, S.C., Mavridis, D., Navarese, E., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385 (2015), 2047–2056.
11. Bakris, G.L., Current and future potassium binders. Nephrol News Issues, 30(4), 2016 Apr suppl 27–31.
12. Sarafidis, P.A., Georgianos, P.I., Bakris, G.L., Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother 16 (2015), 2205–2215.
13. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349 (1997), 1857–1863.
15. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
16. Hou, F.F., Zhang, X., Zhang, G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006), 131–140.
17. Lewis, E.J., Hunsicker, L.G., Bain, R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993), 1456–1462.
18. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
19. Wright, J.T., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
20. Miao, Y., Dobre, D., Heerspink, H.J., et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54 (2011), 44–50.
21. Weinberg, J.M., Appel, L.J., Bakris, G., et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169 (2009), 1587–1594.
22. Perkovic, V., Agarwal, R., Fioretto, P., et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 90 (2016), 1175–1183.
23. Navaneethan, S.D., Nigwekar, S.U., Sehgal, A.R., et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 (2009), 542–551.
24. Bolignano, D., Palmer, S.C., Navaneethan, S.D., et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev, 4, 2014, CD007004.
25. Haller, H., Bertram, A., Stahl, K., et al. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?. Curr Hypertens Rep, 18, 2016, 41.
26. Bakris, G.L., Agarwal, R., Chan, J.C., et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 314 (2015), 884–894.
27. Reardon, L.C., Macpherson, D.S., Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. Arch Intern Med 158 (1998), 26–32.
28. Johnson, E.S., Weinstein, J.R., Thorp, M.L., et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 19 (2010), 266–272.
29. Khosla, N., Kalaitzidis, R., Bakris, G.L., Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30 (2009), 418–424.
30. Einhorn, L.M., Zhan, M., Hsu, V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169 (2009), 1156–1162.
31. Korgaonkar, S., Tilea, A., Gillespie, B.W., et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 5 (2010), 762–769.
32. Luo, J., Brunelli, S.M., Jensen, D.E., et al. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol 11 (2016), 90–100.
33. Nakhoul, G.N., Huang, H., Arrigain, S., et al. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease. Am J Nephrol 41 (2015), 456–463.
34. Chen, Y., Sang, Y., Ballew, S.H., et al. Race, Serum Potassium, and Associations With ESRD and Mortality. Am J Kidney Dis 70 (2017), 244–251.
35. Chang, A.R., Sang, Y., Leddy, J., et al. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension 67 (2016), 1181–1188.
36. Sterns, R.H., Rojas, M., Bernstein, P., et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?. J Am Soc Nephrol 21 (2010), 733–735.
37. Scherr, L., Ogden, D.A., Mead, A.W., et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 264 (1961), 115–119.
38. Lepage, L., Dufour, A.C., Doiron, J., et al. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clin J Am Soc Nephrol 10 (2015), 2136–2142.
39. Harel, Z., Harel, S., Shah, P.S., et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126 (2013), 264.e9–264.e24.
40. McGowan, C.E., Saha, S., Chu, G., et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 102 (2009), 493–497.
41. Watson, M.A., Baker, T.P., Nguyen, A., et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis 60 (2012), 409–4016.
42. Ingelfinger, J.R., A new era for the treatment of hyperkalemia?. N Engl J Med 372 (2015), 275–277.
43. Packham, D.K., Rasmussen, H.S., Singh, B., New agents for hyperkalemia. N Engl J Med 372 (2015), 1571–1572.
44. Epstein, M., Pitt, B., Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother 17 (2016), 1435–1448.
45. Lesko, L.J., Offman, E., Brew, C.T., et al. Evaluation of the potential for drug interactions with patiromer in healthy volunteers. J Cardiovasc Pharmacol Ther 22 (2017), 434–446.
46. Stavros, F., Yang, A., Leon, A., et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One, 9, 2014, e114686.
47. Pitt, B., Anker, S.D., Bushinsky, D.A., et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32 (2011), 820–828.
48. Weir, M.R., Bakris, G.L., Bushinsky, D.A., et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372 (2015), 211–221.
49. Bakris, G.L., Pitt, B., Weir, M.R., et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA 314 (2015), 151–161.
50. Packham, D.K., Rasmussen, H.S., Lavin, P.T., et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372 (2015), 222–231.
51. Kosiborod, M., Rasmussen, H.S., Lavin, P., et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312 (2014), 2223–2233.
52. Pitt, B., Bakris, G.L., Bushinsky, D.A., et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17 (2015), 1057–1065.
53. Relypsa, Inc. NCT03071263: Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease (AMBER). Available at: https://clinicaltrials.gov/ct2/show/NCT03071263?term=AMBER&rank=6. Accessed May 2, 2017.
54. Weir, M.R., Mayo, M.R., Garza, D., et al. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens 35:suppl 1 (2017), S57–S63.
55. Georgianos, P.I., Sarafidis, P.A., Sinha, A.D., et al. Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals?. Am J Nephrol 41 (2015), 400–408.
56. Bushinsky, D.A., Rossignol, P., Spiegel, D.M., et al. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. Am J Nephrol 44 (2016), 404–410.
57. Georgianos, P.I., Sarafidis, P.A., New Potassium Binders: A Call to Test Their Efficacy and Safety in Dialysis Patients. Am J Kidney Dis 67 (2016), 165–166.